B+
Bull case
30%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
CYRX
CryoPortFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings company release was materially better than the pre-print monitoring setup: revenue growth accelerated, commercial CGT and services trends stayed strong, adjusted EBITDA improved year over year, and management raised FY26 revenue guidance to $192 million-$196 million from $190 million-$194 million. That supports a modestly stronger positive bias than the April 28, 2026 baseline.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Cryoport remains loss-making despite EBITDA improvement, so any growth slowdown could delay the pathway to profitability.
Momentum
93
Value
41
Sentiment
18
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $14.00 · Bear $8.50Analysis 2026-05-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $20.13
Why
Momentum93 · Δ7d +1.3
Value41 · Δ7d -0.1
Sentiment18 · Δ7d -3.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Cryoport remains loss-making despite EBITDA improvement, so any growth slowdown could delay the pathway to profitability.
- • Demand is still partly tethered to customer CGT approvals, filings, and program progression, which Cryoport does not control directly.
- • This is still a low-coverage T+1 earnings follow-up with no trustworthy post-print analyst target-change or estimate-revision set confirmed from the checked sources.
Catalyst clock
2026-05-04
Q1 2026 revenue growth, EBITDA improvement, and raised FY26 guide reset the near-term earnings setup
Lead driver: Value · See fundamentals
Momentum
93
8% active weight
Current posture
7d trendFlat
Δ7d
+1.3
Δ21d
+7.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
18
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.6
Δ21d
-5.8
Why this grade
Composite grade F. Momentum 92.9 / Value 40.6 / Sentiment 18.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$910.67M
Beta
1.66
Shares Out
50.65M
P/E (TTM)
8.3
P/S (TTM)
2.59
P/FCF (TTM) · Derived
-44.96
Rev YoY
+7.7%
EPS YoY
-24.2%
Gross Margin
+40.2%
Op Margin
-21.2%
Net Debt
-$180.49M
Current Ratio
2.08
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data